Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

The Supervisory Board of biotechnology company MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015. Dr. Söhngen is co-founder of PAION AG and PAION Deutschland GmbH. She will remain at PAION in her role as Chief Medical Officer (CMO)... [more]

The Supervisory Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) today appointed Dr. Mariola Söhngen, co-founder of PAION AG (and Management Board member up to October 31, 2015, as Chief Medical Officer; CMO), as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015. She will be in... [more]

Interim Report 1st Quarter 2015

Download PDF (0,4 MB)

Annual Report 2014

Download PDF (0,4 MB)